Efficient, Large-Scale Virus-Like Particle Manufacturing For Gene Editing By A GMP-Compliant Flow Electroporation Platform

Virus-like particles (VLPs) are non-infectious, virally-derived nanoparticles that can deliver cargo for genome editing. They are a safer alternative to traditional viral vectors because they do not integrate into the genome. Scaling up VLP production, especially for clinical applications, can be challenging and time-consuming due to the need for multiple optimization rounds and concerns about batch-to-batch consistency when using chemical methods.

A GMP-compliant flow electroporation platform offers a solution for manufacturing clinical-scale VLPs. This approach consistently produces high yields of functional VLPs and enables effective gene editing in primary human cells at therapeutically relevant loci, such as B2M and PD-1. Furthermore, VLP production via electroporation demonstrates favorable kinetics, supporting a one-day manufacturing process. The method also allows for scalable VLP production across a 400-fold volume range with minimal re-optimization, facilitating transfection of over one billion cells per production.

To learn more about how this technology can address the needs of future clinical and commercial manufacturing for gene editing applications, download the full poster.